Clinical Trial Update: Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing GDC-0980 with Everolimus in patients with metastatic renal cell carcinoma who progressed after VEGF-targeted therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• GDC-0980

Snippet

Sponsor: Genentech, Inc. | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED